title: Two important determinants may play a role in the success of the FinHer Trial.
authors.forename: Metin
authors.initials: M
authors.lastname: Isik
authors.forename: Omer
authors.initials: O
authors.lastname: Dizdar
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D043823:Taxoids / Q000008:administration & dosage*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D000068878:Trastuzumab